Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Aprea TherapeuticsINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | terminated | Phase 2 / Phase 3 | 126 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 24, 2019 |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 2 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | terminated | Phase 1 / Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | terminated | Phase 1 / Phase 2 | 19 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01813214 | The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma | terminated | Phase 2 | 5 | Georgetown UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Feb 18, 2019 | clinicaltrials |
| NCT01542255 | Metronomic Therapy in Patients With Metastatic Melanoma | terminated | Phase 2 | 7 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 4 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02050321 | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00961376 | Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) | terminated | Phase 2 | 5 | Providence Health & ServicesOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01453361 | Phase II FANG™ in Advanced Melanoma | terminated | Phase 2 | 18 | Gradalis, Inc.INDUSTRY | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT01702896 | Interleukin-2 in Metastatic Melanoma | terminated | Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01543464 | Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients | terminated | Phase 2 | 41 | Inge Marie SvaneOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01689974 | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | terminated | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01721603 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | terminated | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01740401 | CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma | terminated | Phase 2 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01495988 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | terminated | Phase 2 | 10 | Melanoma Research Foundation Breakthrough ConsortiumOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01009515 | Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | terminated | Phase 2 | 19 | New Mexico Cancer Research AllianceOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | terminated | Phase 2 | 14 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 29, 2017 | clinicaltrials |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | terminated | Phase 1 / Phase 2 | 35 | Scancell LtdINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01042366 | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | terminated | Phase 2 | 16 | John KirkwoodOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT01271907 | Drosophila-generated CTL | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00849875 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Jul 12, 2017 | clinicaltrials |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | terminated | Phase 1 / Phase 2 | 39 | University of IowaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01701037 | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | terminated | Phase 2 | 13 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01586195 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | terminated | Phase 2 | 31 | Genentech, Inc.INDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT01551693 | STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01754376 | Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | terminated | Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | terminated | Phase 1 / Phase 2 | 9 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00707161 | Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00601861 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | terminated | Phase 2 | 1 | Novo Nordisk A/SINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01705392 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | terminated | Phase 2 | 2 | Haukeland University HospitalOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma(LOGIC) | terminated | Phase 2 | 15 | Array BioPharmaINDUSTRY | 6 | Jan 9, 2017 | clinicaltrials |
| NCT00068666 | Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System | terminated | Phase 2 | 41 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01973608 | MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma | terminated | Phase 2 | 12 | EMD SeronoINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01092728 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | terminated | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2019source: clinicaltrials